enGene Holdings (enGene Holdings) ROCE % : -48.40% (As of Jan. 2024)

View and export this data going back to 2023. Start your Free Trial

What is enGene Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. enGene Holdings's annualized ROCE % for the quarter that ended in Jan. 2024 was -48.40%.

enGene Holdings ROCE % Historical Data

The historical data trend for enGene Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enGene Holdings ROCE % Chart

enGene Holdings Annual Data

Trend

Oct20

Oct21

Oct22

Oct23

ROCE %

-155.93

-150.36

-188.94

enGene Holdings Quarterly Data
	Oct20	Oct21	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial					-132.79	-247.92	-59.87	-547.24	-48.40

enGene Holdings ROCE % Calculation

enGene Holdings's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	-94.947	/	( ( (23.909 - 5.104)	+	(86.959 - 5.257) )	/ 2 )
	=	-94.947	/	( (18.805	+	81.702)	/ 2 )
	=	-94.947	/	50.2535
	=	-188.94 %

enGene Holdings's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-40.712	/	( ( (86.959 - 5.257)	+	(93.421 - 6.905) )	/ 2 )
	=	-40.712	/	( ( 81.702	+	86.516 )	/ 2 )
	=	-40.712	/	84.109
	=	-48.40 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

enGene Holdings (NAS:ENGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

enGene Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of enGene Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

enGene Holdings (enGene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » enGene Holdings Inc (NAS:ENGN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7171 Rue Frederick Banting, Saint-Laurent, QC, CAN, H4S 1Z9

Website

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Executives

Richard M Glickman	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jason David Hanson	director, officer: Chief Executive Officer	8125 NORTH HAYDEN ROAD, SCOTTSDALE AZ 85258-2463
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Richard Paul Bryce	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Fonds De Solidarite Des Travailleurs Du Quebec	10 percent owner	545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4
Gerald A Brunk	director	C/O MDS CAPITAL, 245 FIRST ST., STE 1800, CAMBRIDGE MA 02142
Jasper Bos	director	BOUNDARY HALL, PO BOX 1093, CRICKET SQUARE, GRAND CAYMAN E9 KY1-1102
Grassin Alexandre Jean-rene Erwan	officer: Int. Chief Financial Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Anthony Tzeyew Cheung	officer: Chief Technology Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Alexander Julian Nichols	officer: Pres. & Chief Operating Ofc.	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
James Crowley Sullivan	officer: Chief Scientific Officer	7171 RUE FREDERICK BANTING, SAINT-LAURENT A8 H4S 1Z9
Forbion Growth Sponsor Feac I B.v.	10 percent owner	GOOIMEER 2 35,, NAARDEN P7 1411DC
Forbion Growth Opportunities Fund I Cooperatief U.a.	10 percent owner	GOOIMEER 235, 1411 DC, NAARDEN P7 00000
Forbion Growth Management B.v.	10 percent owner	C/O FORBION EUROPEAN ACQUISITION CORP., 4001 KENNETT PIKE, SUITE 302, WILMINGTON DE 19807

enGene Holdings (enGene Holdings) Headlines

From GuruFocus

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

By PRNewswire • 12-22-2023

enGene Appoints Ryan Daws as Chief Financial Officer

By PRNewswire • 11-29-2023

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

By PRNewswire • 12-19-2023